Multifunctional stimuli-responsive niosomal nanoparticles for co-delivery and co-administration of gene and bioactive compound: In vitro and in vivo studies

This study aims to optimize niosomes for carrying and delivering the anticancer agents and genes, simultaneously. We synthesized new cationic niosomal formulations containing Tween 80, Tween 60, cholesterol, and dioleoyl-3-trimethylammonium propane (DOTAP) as a platform to enhance transfection efficacy and stability. Curcumin as an anticancer drug was entrapped with high efficacy inside stable spherical niosomes with sufficient positive charges of about + 27 mV. Loading niosomal curcumins with microRNA-34a (miR-34a) decreased the surface charge to + 15 mV and enhanced the diameter to near 68 nm. The in vitro studies were performed to investigate the cytotoxicity, cellular uptake, and gene expression profiling of normal and cancer cells treated by free curcumin, free miR-34a, niosomal curcumin (NCur), niosomal miR-34a (NmiR), niosomal curcumin + miR34a (NCur-miR) which is termed as co-delivery, and niosomal curcumin + niosomal miR-34a which is termed as co-administration. Results showed that co-delivery caused more cytotoxicity, uptake, and anticancer activity in cancer cells than in other groups. Most importantly, niosomal and free forms of curcumin and miR-34a showed less toxicity to normal human cells. Besides, the effect of these anticancer agents was studied on the 4 T1 xenografted Balb/C mouse tumor model. Co-delivery of curcumin and miR-34a to cancer models caused a higher tumor inhibition rate than other groups. Thus, a combined therapy of curcumin and miR-34a using the new cationic niosomal delivery can be recognized as a prominent strategy for more effective cancer treatments.

Automated summary

This study optimized niosomes for carrying and delivering anticancer agents and genes, showing that co-delivery of curcumin and miR-34a using the new cationic niosomal delivery system can be recognized as a prominent strategy for more effective cancer treatments. Cancer cells treated with co-delivery showed higher cytotoxicity, uptake, and anticancer activity, while showing less toxicity to normal human cells. In addition, the co-delivery of curcumin and miR-34a in the 4T1 xenografted Balb/C mouse tumor model resulted in a higher tumor inhibition rate compared to other groups.